Pnpla2 was significantly upregulated (p < 0.05) in liver hepatocellular carcinoma (LIHC), prostate adenocarcinoma (PRAD), thyroid carcinoma (THCA), and cholangiocarcinoma (CHOL), while significantly downregulated (p < 0.05) in breast invasive carcinoma (BRCA), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and pheochromocytoma and paraganglioma (PCPG). Here, PNPLA2 is linked to cholangiocarcinoma.